Karyopharm Therapeutics Inc.

KPTI Healthcare Biotechnology

Karyopharm Therapeutics Inc.’s revenue for fiscal 2025 (year ended December 2025) was $146.1 million, up 0.57% from fiscal 2024. In the quarter to June 2026, revenue fell 11.9%, EPS grew 46.3%, free cash flow fell 33.3% and total debt rose 36.6%, each against the same quarter a year earlier.

0.39 0.04 +11.43%
Market cap
$8.0M
P/E
0.0×
Fwd P/E
−2.1×
Dividend yield
—
F-score
3/9
Altman Z
−23.89
Beneish M
−8.05
Dividend safety
n/a

A Balance Sheet is a financial statement that provides a snapshot of a company's assets, liabilities, and shareholders' equity at a specific point in time. It follows the formula: Assets = Liabilities + Shareholders' Equity. Key components include current and non-current assets, current and long-term liabilities, and equity. The Balance Sheet helps businesses and investors evaluate financial stability, liquidity, and capital structure. It's essential for assessing the company's ability to meet its obligations and fund future operations.

Dec '16 Dec '17 Dec '18 Dec '19 Dec '20 Dec '21 Dec '22 Dec '23 Dec '24 Dec '25
Total current assets
131.64 148.42 334.61 278.57 276.53 275.61 350.16 233.92 156.46 103.15
Total non-current assets
48.75 31.87 6.58 16.39 36.52 29.70 8.01 6.52 7.96 5.27
Total Assets
180.39 180.29 341.19 294.96 313.05 305.31 358.17 240.44 164.42 108.42
Total current liabilities
16.48 49.47 46.90 46.35 60.20 73.72 65.91 69.48 92.26 92.06
Total non-current liabilities
1.67 1.36 111.12 198.84 202.30 311.26 308.92 307.17 258.17 309.28
Total liabilities
18.14 50.83 158.02 245.19 262.50 384.98 374.83 376.64 350.44 401.34
Common Equity (Total)
162.24 129.46 183.17 49.77 50.55 (79.67) (16.66) (136.21) (186.02) (292.93)
Shareholders Equity (Total)
162.24 129.46 183.17 49.77 50.55 (79.67) (16.66) (136.21) (186.02) (292.93)
Total Debt
— — 102.66 111.50 119.85 171.61 172.98 170.92 187.37 226.90

Show all line items

In millions of $ except per-share values · columns are period end dates